ABT 301
Alternative Names: ABT-301; MPT-0E028Latest Information Update: 14 Jun 2025
At a glance
- Originator Formosa Pharmaceuticals; Taipei Medical University
- Developer AnBogen Therapeutics; Formosa Pharmaceuticals; Taipei Medical University
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Idiopathic pulmonary fibrosis; Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Taiwan (PO)
- 23 Oct 2024 Preclinical trials in Colorectal cancer in Taiwan (SC), prior to October 2024
- 23 Oct 2024 Pharmacodynamics and immunogenicity data from preclinical trials in Colorectal cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)